Core Laboratories (NYSE:CLB) Issues Q4 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 0.120-0.200 for the period, compared to the consensus estimate of 0.190. The company issued revenue guidance of $128.5 million-$134.5 million, compared to the consensus revenue estimate of $134.2 million.

Core Laboratories Price Performance

CLB stock opened at $10.64 on Friday. The company has a current ratio of 2.19, a quick ratio of 1.55 and a debt-to-equity ratio of 0.13. Core Laboratories has a one year low of $9.13 and a one year high of $20.36. The firm has a market capitalization of $488.16 million, a PE ratio of 28.00, a P/E/G ratio of 2.07 and a beta of 1.14. The firm has a 50-day moving average of $11.00 and a two-hundred day moving average of $13.92.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, October 28th. The oil and gas company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $132.08 million during the quarter, compared to analysts’ expectations of $131.87 million. Core Laboratories had a net margin of 3.42% and a return on equity of 8.94%. The business’s revenue for the quarter was down 1.8% on a year-over-year basis. During the same period last year, the company posted $0.22 earnings per share. On average, analysts forecast that Core Laboratories will post 0.56 earnings per share for the current year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Monday, November 9th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, November 9th. Core Laboratories’s payout ratio is 7.14%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Johnson Rice upgraded Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Thursday, August 13th. Finally, Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Core Laboratories News Roundup

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Third-quarter revenue increased 6% sequentially to $132.1 million, while adjusted EPS rose 46% sequentially to $0.16. The company also repurchased 87,873 shares for approximately $1.1 million and maintained its quarterly dividend at $0.01 per share. Core Lab Reports Third Quarter 2026 Results
• Neutral Sentiment: Management’s fourth-quarter outlook calls for revenue of $128.5 million to $134.5 million and EPS of $0.12 to $0.20. The midpoint implies a sequential revenue decline but leaves room for results near the current consensus range. The board also approved a $0.01-per-share dividend payable November 30 to shareholders of record November 9. Core Laboratories Provides Fourth-Quarter Guidance
• Negative Sentiment: Although adjusted EPS of $0.16 was in line with some analyst estimates, it was below the $0.17 Zacks consensus and down from $0.22 a year earlier. GAAP EPS was $0.12, net income fell sharply year over year, and revenue declined 2% from the prior-year quarter. Core Laboratories Q3 Earnings Miss Estimates
• Negative Sentiment: Margins remain the main concern: adjusted operating income rose sequentially but fell 24% year over year, while free cash flow was only $1.7 million. Fourth-quarter revenue guidance has a midpoint slightly below consensus, and the EPS range includes $0.12—well below the $0.19 consensus estimate—reinforcing investor concerns about near-term earnings momentum.

Core Laboratories Company Profile

Core Laboratories N.V. (NYSE: CLB) is a global provider of proprietary reservoir description and production enhancement services and products for the energy industry. The company helps oil and natural gas producers evaluate reservoirs, improve well performance, and optimize the recovery of hydrocarbons.

Its reservoir description activities include geological and geochemical analysis, petrophysical services, core and fluid analysis, and laboratory testing used to characterize subsurface formations.